Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic, presented her research findings at the international medical congress “KOREADERMA 2025.”
She presented clinical research on lower eyelid rejuvenation and laser treatments, promoting a scientific approach to aesthetic medicine.
IRVINE, Calif. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced that Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic, presented her research findings at the international medical congress “KOREADERMA 2025.”
“KOREADERMA” is one of the largest international congresses in Asia in the fields of dermatology and aesthetic medicine, organized by The Association of Korean Dermatologists. It is known as a global forum where physicians and researchers from around the world share the latest knowledge and technologies across a wide range of fields, including basic dermatological research, clinical applications, energy-based devices, skincare, and regenerative medicine. Dr. Ayaka Nishikawa was invited to speak at KOREADERMA 2025, held in Seoul, South Korea, for three days starting Friday, October 31, 2025, in recognition of her numerous academic presentations and extensive clinical experience.
At the congress, Dr. Nishikawa presented two clinical studies: one on lower eyelid rejuvenation treatments and another on laser therapy for pigmented lesions. In the former, she introduced a method that combines injectable treatments such as hyaluronic acid with energy-based devices to naturally tighten sagging skin and fine wrinkles. In the latter, she reported the results of clinical studies on laser treatments for pigmented lesions using a 532-nanometer (nm) wavelength laser. She introduced the features of the CLASSYS S, an automated laser device, and demonstrated that its uniform output and enhanced precision could reduce the burden on the skin while achieving stable treatment results. Through these studies, Dr. Nishikawa emphasized the importance of developing aesthetic medicine not merely as a means of changing appearance, but as a science-based medical practice that helps individuals lead more confident and positive lives. Her practical and accessible presentation drew strong interest from physicians and researchers from various countries.
In recent years, rapid technological innovation in the field of aesthetic medicine has increased the importance of not only clinical practice but also the dissemination of specialized knowledge and international collaboration. To meet increasingly diverse needs, it is essential to combine cutting-edge technology with a global perspective and flexible thinking. SBC Medical Group will continue to share its advanced initiatives with the world through exchanges with international congresses and research institutions, contributing to the sustainable development of aesthetic medicine.
Overview of “KOREADERMA 2025”
Venue: Coex Magok (Seoul, South Korea)
Dates: October 31 (Fri) – November 2 (Sun), 2025
Official Website: https://www.koreaderma.org/home
Presentation Topics:
・ Combined Approach to Lower Eyelid Rejuvenation Using Injectables and Energy-based Devices
・ Innovation in 532nm Laser Dermatology: Automated Laser Device for Pigment Lesions (CLASSYS S)
After graduating from the School of Medicine at Yokohama City University, Dr. Ayaka Nishikawa joined Shonan Beauty Clinic in 2015 as a dermatologist specializing in aesthetic medicine. In 2018, she was appointed Chief Director of Dermatology and currently oversees a wide range of initiatives across the SBC Medical Group, including the development of new dermatological treatments, technical training for doctors and nurses, and safety management. Through the analysis of clinical cases, she is dedicated to promoting evidence-based medical practice and actively engages in academic activities such as presenting at domestic and international conferences and contributing to medical journals. In recognition of her achievements, she was appointed Visiting Professor at SBC Tokyo Medical University in 2023. For more information on Dr. Nishikawa’s professional profile, please visit [here].
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/
Contacts
SBC Medical Group Holdings Incorporated (Asia)
Hikaru Fukui / Head of Investor Relations E-mail: ir@sbc-holdings.com
Daisuke Murakami / Public Relations Officer E-mail: pr@sbc.or.jp
ICR LLC (In the US)
Bill Zima / Managing Partner Email: bill.zima@icrinc.com